Risk scores for death in patients with cancer-related venous thromboembolism. still a long road ahead

Patients with cancer have an increased risk of venous thromboembolism (VTE) compared with non-cancer patients.1 In these patients, the risk of VTE is variable and seems to be related to several factors including cancer site and extension, anti-cancer treatment and several intrinsic patient characteristics.2,3 Low-molecular-weight heparin (LMWH) has been for many years the treatment of choice for cancer-related VTE. The European Society of Cardiology (ESC) guidelines published in 2019 opened to the use of direct oral anticoagulants (DOACs) for treatment of cancerrelated VTE.